Phase III study CheckMate 067 reported improved progression-free survival (PFS) with NIVO+ IPI vs IPI alone. Here, we report results of subgroup analyses in this trial. Treatment-naive MEL pts (N= 945) were randomized 1: 1: 1 to receive NIVO (3 mg/kg Q2W)+ placebo (PBO), or NIVO+ IPI (1 mg/kg+ 3 mg/kg Q3W X 4) followed by NIVO 3 mg/kg Q2W, or to IPI (3 mg/kg Q3W X 4)+ PBO until disease progression or unacceptable toxicity. PFS, a co-primary endpoint, was evaluated in predefined subgroups. In the total population, median PFS was 11.5 months for NIVO+ IPI vs 2.9 months for IPI alone (hazard ratio [HR] vs IPI, 0.42; P< 0.00001), and was 6.9 months for NIVO alone (HR vs IPI, 0.57; P< 0.00001). Numerically longer PFS was observed with the combination vs NIVO or IPI alone in all predefined subgroups, including baseline lactate dehydrogenase> upper limit of normal (NIVO+ IPI: 4.2 months [95% CI: 2.8-9.3] vs NIVO: 2.8 months [95% CI: 2.6-4.0] vs IPI: 2.6 months [95% CI: 2.6-2.8]) and age